Transitioning to Tubeless Automated Insulin Delivery: Clinical Insights from the RADIANT Trial and Contemporary Management of Type 1 Diabetes

The RADIANT trial demonstrates a significant HbA1c reduction of 0.8% when transitioning directly from multiple daily injections (MDI) to tubeless automated insulin delivery (AID) compared to continuing MDI.
Safety outcomes were robust, with zero episodes of diabetic ketoacidosis (DKA) or severe hypoglycemia reported in the AID group over 13 weeks.
Direct transition from MDI to AID simplifies the clinical workflow, offering a viable therapeutic option for patients with suboptimal glycemic control (HbA1c 7.5–11.0%).
Integrating genetic susceptibility data suggests that metabolic interventions are increasingly critical as environmental factors exacerbate glycemic instability in predisposed populations.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

The RADIANT trial demonstrates a significant HbA1c reduction of 0.8% when transitioning directly from multiple daily injections (MDI) to tubeless automated insulin delivery (AID) compared to continuing MDI.
Safety outcomes were robust, with zero episodes of diabetic ketoacidosis (DKA) or severe hypoglycemia reported in the AID group over 13 weeks.
Direct transition from MDI to AID simplifies the clinical workflow, offering a viable therapeutic option for patients with suboptimal glycemic control (HbA1c 7.5–11.0%).
Integrating genetic susceptibility data suggests that metabolic interventions are increasingly critical as environmental factors exacerbate glycemic instability in predisposed populations.

Sign in free to continue reading